Thermo Fisher Scientific (TMO) 10-Q 1 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 28, 2020shares
Entity Listings [Line Items]
Entity Central Index Key	0000097745
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 28, 2020
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	394,951,104
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
Floating Rate Notes due 2020
Entity Listings [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2020
Trading Symbol	TMO /20A
Security Exchange Name	NYSE
2.150% Notes due 2022
Entity Listings [Line Items]
Title of 12(b) Security	2.150% Notes due 2022
Trading Symbol	TMO 22A
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 2,981	$ 2,399
Accounts receivable, less allowances of $101 and $102	4,508	4,349
Inventories	3,454	3,370
Contract assets, net	658	603
Other current assets	1,137	1,172
Total current assets	12,738	11,893
Property, Plant and Equipment, Net	4,736	4,749
Acquisition-related Intangible Assets, Net	13,543	14,014
Other Assets	2,057	2,011
Goodwill	25,614	25,714
Total Assets	58,688	58,381
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	738	676
Accounts payable	1,599	1,920
Accrued payroll and employee benefits	755	1,010
Contract liabilities	938	916
Other accrued expenses	1,470	1,675
Total current liabilities	5,500	6,197
Deferred Income Taxes	2,137	2,192
Other Long-term Liabilities	3,261	3,241
Long-term Obligations	19,231	17,076
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 435,242,143 and 434,416,804 shares issued	435	434
Capital in excess of par value	15,186	15,064
Retained earnings	22,791	22,092
Treasury stock at cost, 40,291,039 and 35,676,421 shares	(6,765)	(5,236)
Accumulated other comprehensive items	(3,088)	(2,679)
Total shareholders' equity	28,559	29,675
Total Liabilities and Shareholders' Equity	$ 58,688	$ 58,381

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 101	$ 102
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	435,242,143	434,416,804
Treasury Stock at Cost (in shares)	40,291,039	35,676,421

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Revenues
Revenues	$ 6,230	$ 6,125
Costs and Operating Expenses:
Selling, general and administrative expenses	1,551	1,528
Research and development expenses	245	248
Restructuring and other costs, net	38	11
Total costs and operating expenses	5,324	5,205
Operating Income	906	920
Interest Income	36	67
Interest Expense	(126)	(189)
Other Income, Net	12	19
Income Before Income Taxes	828	817
Provision for Income Taxes	(40)	(2)
Net Income	$ 788	$ 815
Earnings per Share
Basic (in dollars per share)	$ 1.99	$ 2.04
Diluted (in dollars per share)	$ 1.97	$ 2.02
Weighted Average Shares
Basic (in shares)	397	400
Diluted (in shares)	400	403
Product [Member]
Revenues
Revenues	$ 4,630	$ 4,720
Costs and Operating Expenses:
Cost of revenues	2,340	2,414
Service [Member]
Revenues
Revenues	1,600	1,405
Costs and Operating Expenses:
Cost of revenues	$ 1,150	$ 1,004

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Comprehensive Income
Net income	$ 788	$ 815
Currency translation adjustment:
Currency translation adjustment (net of tax provision of $22 and $45)	(357)	(15)
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $19 and $0)	(62)	0
Reclassification adjustment for losses included in net income (net of tax benefit of $1 and $1)	1	2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision of $5 and $0)	5	1
Amortization of net loss included in net periodic pension cost (net of tax benefit of $1 and $1)	4	1
Total other comprehensive items	(409)	(11)
Comprehensive Income	$ 379	$ 804

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 22	$ 45
Tax benefit on unrealized holding losses on hedging instruments arising during the period	19	0
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	1	1
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	5	0
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 1	$ 1

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Operating Activities
Net income	$ 788	$ 815
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	149	133
Amortization of acquisition-related intangible assets	425	422
Change in deferred income taxes	(41)	(106)
Stock-based compensation	46	44
Other non-cash expenses, net	64	18
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable	(218)	(29)
Inventories	(141)	(140)
Accounts payable	(241)	(129)
Contributions to retirement plans	(32)	(32)
Other	(443)	(347)
Net cash provided by operating activities	356	649
Investing Activities
Acquisitions, net of cash acquired	(4)	(1)
Purchase of property, plant and equipment	(253)	(201)
Proceeds from sale of property, plant and equipment	4	6
Other investing activities, net	(7)	15
Net cash used in investing activities	(260)	(181)
Financing Activities
Net proceeds from issuance of debt	2,185	0
Repayment of debt	(1)	(1)
Proceeds from issuance of commercial paper	382	100
Repayments of commercial paper	(321)	(787)
Purchases of company common stock	(1,500)	(750)
Dividends paid	(76)	(68)
Net proceeds from issuance of company common stock under employee stock plans	48	81
Other financing activities, net	(98)	0
Net cash provided by (used in) financing activities	619	(1,425)
Exchange Rate Effect on Cash	(127)	(32)
Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	588	(989)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	2,422	2,117
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 3,010	$ 1,128

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2018			432				29
Balance at Dec. 31, 2018	$ 27,586	$ 4	$ 432	$ 14,621	$ 18,696	$ 4	$ (3,665)	$ (2,498)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				1
Issuance of shares under employees' and directors' stock plans	81		$ 1	106			$ (26)
Stock-based compensation	44			44
Purchases of company common stock (in shares)							3
Purchases of company common stock	(750)						$ (750)
Dividends declared	(76)				(76)
Net income	815				815
Other comprehensive items	(11)							(11)
Balance (in shares) at Mar. 30, 2019			433				33
Balance at Mar. 30, 2019	27,693		$ 433	14,771	19,439		$ (4,441)	(2,509)
Balance (in shares) at Dec. 31, 2019			434				36
Balance at Dec. 31, 2019	29,675	$ (1)	$ 434	15,064	22,092	$ (1)	$ (5,236)	(2,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				0
Issuance of shares under employees' and directors' stock plans	48		$ 1	76			$ (29)
Stock-based compensation	46			46
Purchases of company common stock (in shares)							4
Purchases of company common stock	(1,500)						$ (1,500)
Dividends declared	(88)				(88)
Net income	788				788
Other comprehensive items	(409)							(409)
Balance (in shares) at Mar. 28, 2020			435				40
Balance at Mar. 28, 2020	$ 28,559		$ 435	$ 15,186	$ 22,791		$ (6,765)	$ (3,088)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.22	$ 0.19

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 28, 2020, the results of operations for the three-month periods ended March 28, 2020 and March 30, 2019, and the cash flows for the three-month periods ended March 28, 2020 and March 30, 2019. Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 31, 2019, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2019 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2019 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended March 28, 2020. Contract-related Balances Accounts receivable include amounts that have been billed and are currently due from customers. They are recorded at the invoiced amount and do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers. The changes in the allowance for doubtful accounts are as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Beginning Balance $ 102 $ 117 Cumulative effect of accounting change 1 — Provision charged to expense 10 2 Accounts written off (11) (5) Acquisitions, currency translation and other (1) — Ending Balance $ 101 $ 114 Contract assets include revenues recognized in advance of billings and are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract. Contract asset and liability balances are as follows: March 28, December 31, (In millions) 2020 2019 Current Contract Assets, Net $ 658 $ 603 Noncurrent Contract Assets, Net 17 17 Current Contract Liabilities 938 916 Noncurrent Contract Liabilities 617 594 In the first three months of 2020, the company recognized revenue of $405 million that was included in the contract liabilities balance at December 31, 2019. Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Beginning Balance $ 93 $ 92 Provision charged to expense 22 27 Usage (25) (28) Adjustments to previously provided warranties, net — (1) Currency translation (1) — Ending Balance $ 89 $ 90 Inventories The components of inventories are as follows: March 28, December 31, (In millions) 2020 2019 Raw Materials $ 1,069 $ 971 Work in Process 503 517 Finished Goods 1,882 1,882 Inventories $ 3,454 $ 3,370 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic will materially adversely affect the company’s operations through at least the second quarter of 2020. The extent and duration of such impacts are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company expects to adopt this guidance when it is effective in 2021 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures.

Acquisitions and Dispositions

Acquisitions and Dispositions	3 Months Ended
	Mar. 28, 2020
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. Pending Acquisition On March 3, 2020, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of QIAGEN N.V. at a price of €39.00 per share or approximately $11.5 billion (based on exchange rates at the time of the announcement), which includes the assumption of approximately $1.4 billion of net debt. QIAGEN is a leading provider of life science and molecular diagnostic solutions that will expand the company’s capabilities in these fields. QIAGEN reported 2019 revenues of $1.5 billion. The company will commence a tender offer to acquire all of the ordinary shares of QIAGEN. The transaction is expected to close during the first half of 2021, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an Extraordinary General Meeting of QIAGEN’s shareholders, and completion of the tender offer. The company intends to finance the purchase price, including the repayment of indebtedness of QIAGEN, with cash on hand and the net proceeds from issuances of debt. The company is currently evaluating future debt financings and the timing of

Revenue

Revenue	3 Months Ended
	Mar. 28, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenue Disaggregated Revenue Revenue by type is as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues Consumables $ 3,379 $ 3,230 Instruments 1,251 1,490 Services 1,600 1,405 Consolidated revenues $ 6,230 $ 6,125 Revenue by geographic region is as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues (a) North America $ 3,287 $ 3,059 Europe 1,649 1,519 Asia-Pacific 1,118 1,363 Other regions 176 184 Consolidated revenues $ 6,230 $ 6,125 (a) Revenues are attributed to regions based on customer location. Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenue by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 28, 2020 was $8.36 billion. The company will recognize revenue for these performance obligations as they are satisfied, approximately 65% of which is expected to occur within the next twelve months.

Business Segment and Geographic

Business Segment and Geographical Information	3 Months Ended
	Mar. 28, 2020
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information Business Segment Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues Life Sciences Solutions $ 1,774 $ 1,607 Analytical Instruments 1,101 1,322 Specialty Diagnostics 958 957 Laboratory Products and Services 2,730 2,513 Eliminations (333) (274) Consolidated revenues 6,230 6,125 Segment Income (a) Life Sciences Solutions 675 561 Analytical Instruments 171 282 Specialty Diagnostics 236 242 Laboratory Products and Services 295 285 Subtotal reportable segments (a) 1,377 1,370 Cost of revenues charges, net (2) (6) Selling, general and administrative charges, net (6) (11) Restructuring and other costs, net (38) (11) Amortization of acquisition-related intangible assets (425) (422) Consolidated operating income 906 920 Interest income (b) 36 67 Interest expense (b) (126) (189) Other income, net (b) 12 19 Income before income taxes $ 828 $ 817 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments. Geographical Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues (c) United States $ 3,139 $ 2,918 China 464 654 Other 2,627 2,553 Consolidated revenues $ 6,230 $ 6,125 (c) Revenues are attributed to countries based on customer location.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 28, 2020
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 5. Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended March 28, March 30, (In millions) 2020 2019 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 174 $ 172 Increases (Decreases) Resulting From: Foreign rate differential (88) (36) Foreign exchange loss on inter-company debt refinancing — (62) Income tax credits (67) (72) Global intangible low-taxed income 61 70 Foreign-derived intangible income (17) (12) Transition tax and other impacts of U.S. tax reform — (20) Excess tax benefits from stock options and restricted stock units (28) (36) Other, net 5 (2) Provision for Income Taxes $ 40 $ 2 The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. Unrecognized Tax Benefits As of March 28, 2020, the company had $1.55 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2020 Balance at Beginning of Year $ 1,552 Additions for tax positions of current year 2 Settlements (7) Balance at End of Period $ 1,547

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 28, 2020
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 6. Earnings per Share Three Months Ended March 28, March 30, (In millions except per share amounts) 2020 2019 Net Income $ 788 $ 815 Basic Weighted Average Shares 397 400 Plus Effect of: Stock options and restricted units 3 3 Diluted Weighted Average Shares 400 403 Basic Earnings per Share $ 1.99 $ 2.04 Diluted Earnings per Share $ 1.97 $ 2.02 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 1 2

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	3 Months Ended
	Mar. 28, 2020
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 7. Debt and Other Financing Arrangements Effective Interest Rate at March 28, March 28, December 31, (Dollars in millions) 2020 2020 2019 Commercial Paper 3.00 % $ 66 $ — Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.16 % 668 673 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.27 % 557 561 3.00% 7-Year Senior Notes, Due 4/15/2023 2.72 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,114 1,121 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 891 897 4.133% 5-Year Senior Notes, Due 3/25/2025 4.28 % 1,100 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 713 717 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 780 785 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 557 561 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 891 897 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 668 673 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 780 785 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.32 % 1,100 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,003 1,009 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 780 785 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,003 1,009 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,114 1,121 Other 16 16 Total Borrowings at Par Value 20,151 17,960 Fair Value Hedge Accounting Adjustments 22 (13) Unamortized Discount, Net (91) (94) Unamortized Debt Issuance Costs (113) (101) Total Borrowings at Carrying Value 19,969 17,752 Less: Short-term Obligations and Current Maturities 738 676 Long-term Obligations $ 19,231 $ 17,076 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 10 for fair value information pertaining to the company’s long-term obligations. In connection with the agreement to acquire QIAGEN (Note 2), the company obtained, but does not currently expect to utilize, up to €9.25 billion of committed financing. The company intends to finance the purchase price, including the repayment of indebtedness of QIAGEN, with cash on hand and the net proceeds from issuances of debt. The company issued senior notes in March and April 2020 (Note 13) to partly fund the acquisition and for general corporate purposes. The company is currently evaluating future debt financings and the timing of such transactions is subject to market and other conditions. The company had a cash outlay of $36 million in 2020 associated with obtaining the bridge commitment included in other financing activities, net, in the accompanying statement of cash flows. In 2020, other income, net includes $17 million of costs for the QIAGEN acquisition, primarily for entering into hedging contracts and amortization of bridge loan commitment fees. Credit Facilities The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021. The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 3.5:1.0. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter. As of March 28, 2020, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $71 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of March 28, 2020, outstanding borrowings under these programs were $66 million with a weighted average remaining period to maturity of 31 days and are classified as short-term obligations in the accompanying balance sheet. Senior Notes Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. In 2018, Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company, issued the Floating Rate Senior Notes due 2020 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2020 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations. Interest Rate Swap Arrangements and related Cross-currency Interest Rate Swap Arrangements The company has entered into LIBOR-based interest rate swap arrangements with various banks. The aggregate amounts of the swaps are equal to the principal amount of the notes and the payment dates of the swaps coincide with the interest payment dates of the note. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 10 for additional information on the interest rate swap arrangements and related cross-currency interest rate swap arrangements. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at March 28, 2020: Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate March 28, Receive Rate 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 2.4686 % 3.00 % (a) The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of March 28, 2020 from 2.47% to a weighted average of 1.17%. The company has entered into $900 million notional value of cross-currency interest rate swaps, which effectively convert a portion of the semi-annual payments related to the variable rate, U.S. dollar denominated, LIBOR-based interest rate swaps to payments on variable rate, euro denominated, EURIBOR-based cross-currency interest rate swaps.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 28, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 8. Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At March 28, 2020, the company’s total environmental liability was approximately $70 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2019 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Intellectual Property Matters On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies, a subsidiary of the company, in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product “supply centers” installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board (PTAB) that found the challenged patent claims invalid. The United States Court of Appeals for the Federal Circuit upheld the PTAB’s ruling finding the challenged claims in the Unisone patent invalid. Unisone had until March 11, 2019 to file an appeal with the United States Supreme Court. Unisone did not appeal that decision, and consequently the case before the United States District Court, which had been stayed pending the outcome of the PTAB decision, resumed with Unisone filing an amended complaint on September 12, 2019 regarding similar patent claims that were not included in the PTAB proceeding. On November 1, 2019, Life Technologies filed two additional covered business method (CBM) challenges with the PTAB regarding Unisone’s new patent claims. On December 16, 2019, the United States District Court granted Life Technologies’ motion to stay the case pending the PTAB’s decision whether to institute a CBM review of the new patent claims. On April 28, 2020, the PTAB granted Life Technologies’ November 1, 2019 CBM petitions and instituted review of all of Unisone’s remaining patent claims.

Comprehensive Income

Comprehensive Income	3 Months Ended
	Mar. 28, 2020
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 9. Comprehensive Income Comprehensive income combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet. Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2019 $ (2,320) $ (71) $ (288) $ (2,679) Other comprehensive items before reclassifications (357) (62) 5 (414) Amounts reclassified from accumulated other comprehensive items — 1 4 5 Net other comprehensive items (357) (61) 9 (409) Balance at March 28, 2020 $ (2,677) $ (132) $ (279) $ (3,088)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	3 Months Ended
	Mar. 28, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 10. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 28, 2020 and December 31, 2019: March 28, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,727 $ 1,727 $ — $ — Investments in common stock, mutual funds and other similar instruments 17 17 — — Warrants 6 — 6 — Insurance contracts 115 — 115 — Derivative contracts 110 — 110 — Total Assets $ 1,975 $ 1,744 $ 231 $ — Liabilities Derivative contracts $ 32 $ — $ 32 $ — Contingent consideration 54 — — 54 Total Liabilities $ 86 $ — $ 32 $ 54 December 31, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,280 $ 1,280 $ — $ — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 131 — 131 — Derivative contracts 37 — 37 — Total Assets $ 1,473 $ 1,299 $ 174 $ — Liabilities Derivative contracts $ 24 $ — $ 24 $ — Contingent consideration 55 — — 55 Total Liabilities $ 79 $ — $ 24 $ 55 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended March 28, March 30, (In millions) 2020 2019 Contingent Consideration Beginning Balance $ 55 $ 37 Payments (1) — Ending Balance $ 54 $ 37 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. March 28, December 31, (In millions) 2020 2019 Notional Amount Interest rate swaps - fair value hedges (described in Note 7) $ 1,000 $ 1,000 Interest rate swaps - cash flow hedges 750 — Cross-currency interest rate swaps - designated as net investment hedges 900 900 Cross-currency interest rate swaps 1,000 — Currency exchange contracts 6,109 2,846 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities March 28, December 31, March 28, December 31, (In millions) 2020 2019 2020 2019 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 22 $ — $ 20 $ 13 Cross-currency interest rate swaps (a) 43 33 — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 45 4 2 11 Cross-currency interest rate swaps (a) — — 10 — Total Derivatives $ 110 $ 37 $ 32 $ 24 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the consolidated balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability March 28, December 31, March 28, December 31, (In millions) 2020 2019 2020 2019 Long-term Obligations $ 1,016 $ 980 $ 22 $ (13) Gain (Loss) Recognized Three Months Ended March 28, March 30, (In millions) 2020 2019 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (36) $ (28) Derivatives designated as hedging instruments - included in other expense, net 36 29 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items (81) — Amount reclassified from accumulated other comprehensive items to other expense, net (2) (3) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 83 156 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 9 37 Included in other expense, net 5 14 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 3 2 Included in other expense, net 40 17 Cross-currency interest rate swaps Included in other expense, net (10) — Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company also uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and certain of its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. The company has also entered into $1 billion notional value of cross currency swaps in anticipation of U.S. dollar term loan borrowings to partially finance the euro purchase price of the QIAGEN acquisition (Note 2). Gains and losses associated with these swaps are recorded in other expense, net. See Note 1 to the consolidated financial statements for 2019 included in the company's Annual Report on Form 10-K and Note 7 herein for additional information on the company's risk management objectives and strategies. Cash Flow Hedge Arrangements In March 2020, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of future debt offerings. Based on the company's conclusion that the debt offerings are probable, the swaps hedge the cash flow risk for each of the interest payments on the planned fixed-rate debt issues. The aggregate fair value of these hedges, net of tax, at March 28, 2020 has been classified as a reduction to accumulated other comprehensive items. One of these hedges was terminated in March 2020, in connection with the debt offering completed in that month. The aggregate fair value of the terminated hedge at that time, net of tax, has been classified as a reduction to accumulated other comprehensive items and will be amortized to interest expense over the term of the related debt issuance. The company had a cash outlay of $62 million in 2020 associated with termination of the arrangement, included in other financing activities, net, in the accompanying statement of cash flows. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 28, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 19,887 $ 19,795 $ 17,736 $ 18,650 Commercial paper 66 66 — — Other 16 16 16 16 $ 19,969 $ 19,877 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 28, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 11. Supplemental Cash Flow Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 88 $ 77 Issuance of stock upon vesting of restricted stock units 73 69 Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: March 28, December 31, (In millions) 2020 2019 Cash and Cash Equivalents $ 2,981 $ 2,399 Restricted Cash Included in Other Current Assets 27 21 Restricted Cash Included in Other Assets 2 2 Cash, Cash Equivalents and Restricted Cash $ 3,010 $ 2,422 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs (

Restructuring and Other Costs (Income), Net	3 Months Ended
	Mar. 28, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 12. Restructuring and Other Costs, Net Restructuring and other costs, net, in the first three months of 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and, to a lesser extent, transaction/integration costs related to recent and pending acquisitions. In the first three months of 2020, severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company’s workforce. As of May 1, 2020, the company has identified restructuring actions that will result in additional charges of approximately $65 million, primarily in 2020, and expects to identify additional actions during 2020 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. During the first three months of 2020, the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ — $ 1 $ 1 Analytical Instruments — — 14 14 Specialty Diagnostics — 4 2 6 Laboratory Products and Services 2 2 18 22 Corporate — — 3 3 $ 2 $ 6 $ 38 $ 46 The principal components of net restructuring and other costs by segment are as follows: Analytical Instruments In the first three months of 2020, the Analytical Instruments segment recorded $14 million of net restructuring and other charges, primarily for employee severance associated with headcount reductions in the U.S. and Europe, and, to a lesser extent, abandoned facility costs. Specialty Diagnostics In the first three months of 2020, the Specialty Diagnostics segment recorded $6 million of net restructuring and other charges, primarily $4 million of charges to selling, general, and administrative expense for third-party transaction/acquisition-related costs. The segment also recorded $2 million of cash restructuring charges for severance and other costs associated with headcount reductions in Europe and the U.S. Laboratory Products and Services In the first three months of 2020, the Laboratory Products and Services segment recorded $22 million of net restructuring and other charges. The segment recorded $2 million of charges to cost of revenues to conform the accounting policies of a recently acquired business with the company’s accounting policies and $2 million of charges to selling, general, and administrative expense for third-party integration costs in connection with this acquisition. The segment recorded $18 million of restructuring and other costs, including $10 million of cash charges for employee severance at businesses streamlining operations. The segment also recorded $8 million of non-cash charges for writedowns of fixed assets to estimated disposal value in connection with the consolidation of commercial production operations in the U.S. Corporate In the first three months of 2020, the company recorded $3 million of net restructuring and other costs for severance at its corporate operations, and, to a lesser extent, abandoned facility costs. The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment Other (a) Total Balance at December 31, 2019 18 $ 10 $ 6 $ 34 Costs incurred in 2020 (c) 23 4 3 30 Reserves reversed (b) (1) — — (1) Payments (10) (3) (2) (15) Balance at March 28, 2020 $ 30 $ 11 $ 7 $ 48 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans. (c) Excludes $9 million of charges for fixed asset writedowns and costs associated with environmental remediation at an abandoned facility. The company expects to pay accrued restructuring costs primarily through 2020.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 28, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Event Debt Issuances Early in the second quarter of 2020, the company issued the following senior notes: (In millions) Principal Value Issued 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) € 600 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) € 600

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts receivable include amounts that have been billed and are currently due from customers. They are recorded at the invoiced amount and do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic will materially adversely affect the company’s operations through at
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company expects to adopt this guidance when it is effective in 2021 using a prospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on the company’s disclosures.
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Acquisitions and Dispositions (

Acquisitions and Dispositions (Policies)	3 Months Ended
	Mar. 28, 2020
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	The changes in the allowance for doubtful accounts are as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Beginning Balance $ 102 $ 117 Cumulative effect of accounting change 1 — Provision charged to expense 10 2 Accounts written off (11) (5) Acquisitions, currency translation and other (1) — Ending Balance $ 101 $ 114
Contract with Customer, Asset and Liability [Table Text Block]	Contract asset and liability balances are as follows: March 28, December 31, (In millions) 2020 2019 Current Contract Assets, Net $ 658 $ 603 Noncurrent Contract Assets, Net 17 17 Current Contract Liabilities 938 916 Noncurrent Contract Liabilities 617 594
Warranty Obligations [Table Text Block]	Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Beginning Balance $ 93 $ 92 Provision charged to expense 22 27 Usage (25) (28) Adjustments to previously provided warranties, net — (1) Currency translation (1) — Ending Balance $ 89 $ 90
Inventories [Table Text Block]	Inventories The components of inventories are as follows: March 28, December 31, (In millions) 2020 2019 Raw Materials $ 1,069 $ 971 Work in Process 503 517 Finished Goods 1,882 1,882 Inventories $ 3,454 $ 3,370

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 28, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenue Revenue by type is as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues Consumables $ 3,379 $ 3,230 Instruments 1,251 1,490 Services 1,600 1,405 Consolidated revenues $ 6,230 $ 6,125 Revenue by geographic region is as follows: Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues (a) North America $ 3,287 $ 3,059 Europe 1,649 1,519 Asia-Pacific 1,118 1,363 Other regions 176 184 Consolidated revenues $ 6,230 $ 6,125 (a) Revenues are attributed to regions based on customer location.

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	3 Months Ended
	Mar. 28, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues Life Sciences Solutions $ 1,774 $ 1,607 Analytical Instruments 1,101 1,322 Specialty Diagnostics 958 957 Laboratory Products and Services 2,730 2,513 Eliminations (333) (274) Consolidated revenues 6,230 6,125 Segment Income (a) Life Sciences Solutions 675 561 Analytical Instruments 171 282 Specialty Diagnostics 236 242 Laboratory Products and Services 295 285 Subtotal reportable segments (a) 1,377 1,370 Cost of revenues charges, net (2) (6) Selling, general and administrative charges, net (6) (11) Restructuring and other costs, net (38) (11) Amortization of acquisition-related intangible assets (425) (422) Consolidated operating income 906 920 Interest income (b) 36 67 Interest expense (b) (126) (189) Other income, net (b) 12 19 Income before income taxes $ 828 $ 817 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues Life Sciences Solutions $ 1,774 $ 1,607 Analytical Instruments 1,101 1,322 Specialty Diagnostics 958 957 Laboratory Products and Services 2,730 2,513 Eliminations (333) (274) Consolidated revenues 6,230 6,125 Segment Income (a) Life Sciences Solutions 675 561 Analytical Instruments 171 282 Specialty Diagnostics 236 242 Laboratory Products and Services 295 285 Subtotal reportable segments (a) 1,377 1,370 Cost of revenues charges, net (2) (6) Selling, general and administrative charges, net (6) (11) Restructuring and other costs, net (38) (11) Amortization of acquisition-related intangible assets (425) (422) Consolidated operating income 906 920 Interest income (b) 36 67 Interest expense (b) (126) (189) Other income, net (b) 12 19 Income before income taxes $ 828 $ 817 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles. (b) The company does not allocate interest or other expense/income, net to its segments.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended March 28, March 30, (In millions) 2020 2019 Revenues (c) United States $ 3,139 $ 2,918 China 464 654 Other 2,627 2,553 Consolidated revenues $ 6,230 $ 6,125 (c) Revenues are attributed to countries based on customer location.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 28, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended March 28, March 30, (In millions) 2020 2019 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 174 $ 172 Increases (Decreases) Resulting From: Foreign rate differential (88) (36) Foreign exchange loss on inter-company debt refinancing — (62) Income tax credits (67) (72) Global intangible low-taxed income 61 70 Foreign-derived intangible income (17) (12) Transition tax and other impacts of U.S. tax reform — (20) Excess tax benefits from stock options and restricted stock units (28) (36) Other, net 5 (2) Provision for Income Taxes $ 40 $ 2
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2020 Balance at Beginning of Year $ 1,552 Additions for tax positions of current year 2 Settlements (7) Balance at End of Period $ 1,547

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Mar. 28, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 28, March 30, (In millions except per share amounts) 2020 2019 Net Income $ 788 $ 815 Basic Weighted Average Shares 397 400 Plus Effect of: Stock options and restricted units 3 3 Diluted Weighted Average Shares 400 403 Basic Earnings per Share $ 1.99 $ 2.04 Diluted Earnings per Share $ 1.97 $ 2.02 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 1 2

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	3 Months Ended
	Mar. 28, 2020
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at March 28, March 28, December 31, (Dollars in millions) 2020 2020 2019 Commercial Paper 3.00 % $ 66 $ — Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.16 % 668 673 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.27 % 557 561 3.00% 7-Year Senior Notes, Due 4/15/2023 2.72 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,114 1,121 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 891 897 4.133% 5-Year Senior Notes, Due 3/25/2025 4.28 % 1,100 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 713 717 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 780 785 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 557 561 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 891 897 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 668 673 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 780 785 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.32 % 1,100 — 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,003 1,009 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 780 785 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,003 1,009 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,114 1,121 Other 16 16 Total Borrowings at Par Value 20,151 17,960 Fair Value Hedge Accounting Adjustments 22 (13) Unamortized Discount, Net (91) (94) Unamortized Debt Issuance Costs (113) (101) Total Borrowings at Carrying Value 19,969 17,752 Less: Short-term Obligations and Current Maturities 738 676 Long-term Obligations $ 19,231 $ 17,076
Schedule of Derivative Instruments [Table Text Block]	Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate March 28, Receive Rate 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 2.4686 % 3.00 % (a) The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of March 28, 2020 from 2.47% to a weighted average of 1.17%.

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Mar. 28, 2020
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2019 $ (2,320) $ (71) $ (288) $ (2,679) Other comprehensive items before reclassifications (357) (62) 5 (414) Amounts reclassified from accumulated other comprehensive items — 1 4 5 Net other comprehensive items (357) (61) 9 (409) Balance at March 28, 2020 $ (2,677) $ (132) $ (279) $ (3,088)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 28, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 28, 2020 and December 31, 2019: March 28, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,727 $ 1,727 $ — $ — Investments in common stock, mutual funds and other similar instruments 17 17 — — Warrants 6 — 6 — Insurance contracts 115 — 115 — Derivative contracts 110 — 110 — Total Assets $ 1,975 $ 1,744 $ 231 $ — Liabilities Derivative contracts $ 32 $ — $ 32 $ — Contingent consideration 54 — — 54 Total Liabilities $ 86 $ — $ 32 $ 54 December 31, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,280 $ 1,280 $ — $ — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 131 — 131 — Derivative contracts 37 — 37 — Total Assets $ 1,473 $ 1,299 $ 174 $ — Liabilities Derivative contracts $ 24 $ — $ 24 $ — Contingent consideration 55 — — 55 Total Liabilities $ 79 $ — $ 24 $ 55
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended March 28, March 30, (In millions) 2020 2019 Contingent Consideration Beginning Balance $ 55 $ 37 Payments (1) — Ending Balance $ 54 $ 37
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. March 28, December 31, (In millions) 2020 2019 Notional Amount Interest rate swaps - fair value hedges (described in Note 7) $ 1,000 $ 1,000 Interest rate swaps - cash flow hedges 750 — Cross-currency interest rate swaps - designated as net investment hedges 900 900 Cross-currency interest rate swaps 1,000 — Currency exchange contracts 6,109 2,846
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities March 28, December 31, March 28, December 31, (In millions) 2020 2019 2020 2019 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 22 $ — $ 20 $ 13 Cross-currency interest rate swaps (a) 43 33 — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 45 4 2 11 Cross-currency interest rate swaps (a) — — 10 — Total Derivatives $ 110 $ 37 $ 32 $ 24 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the consolidated balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability March 28, December 31, March 28, December 31, (In millions) 2020 2019 2020 2019 Long-term Obligations $ 1,016 $ 980 $ 22 $ (13)
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended March 28, March 30, (In millions) 2020 2019 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (36) $ (28) Derivatives designated as hedging instruments - included in other expense, net 36 29 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items (81) — Amount reclassified from accumulated other comprehensive items to other expense, net (2) (3) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 83 156 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 9 37 Included in other expense, net 5 14 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 3 2 Included in other expense, net 40 17 Cross-currency interest rate swaps Included in other expense, net (10) —
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 28, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 19,887 $ 19,795 $ 17,736 $ 18,650 Commercial paper 66 66 — — Other 16 16 16 16 $ 19,969 $ 19,877 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 28, 2020 December 31, 2019 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 19,887 $ 19,795 $ 17,736 $ 18,650 Commercial paper 66 66 — — Other 16 16 16 16 $ 19,969 $ 19,877 $ 17,752 $ 18,666 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 28, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Three Months Ended March 28, March 30, (In millions) 2020 2019 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 88 $ 77 Issuance of stock upon vesting of restricted stock units 73 69
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: March 28, December 31, (In millions) 2020 2019 Cash and Cash Equivalents $ 2,981 $ 2,399 Restricted Cash Included in Other Current Assets 27 21 Restricted Cash Included in Other Assets 2 2 Cash, Cash Equivalents and Restricted Cash $ 3,010 $ 2,422

Restructuring and Other Costs_2

Restructuring and Other Costs (Income), Net (Tables)	3 Months Ended
	Mar. 28, 2020
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the first three months of 2020, the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ — $ 1 $ 1 Analytical Instruments — — 14 14 Specialty Diagnostics — 4 2 6 Laboratory Products and Services 2 2 18 22 Corporate — — 3 3 $ 2 $ 6 $ 38 $ 46
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment Other (a) Total Balance at December 31, 2019 18 $ 10 $ 6 $ 34 Costs incurred in 2020 (c) 23 4 3 30 Reserves reversed (b) (1) — — (1) Payments (10) (3) (2) (15) Balance at March 28, 2020 $ 30 $ 11 $ 7 $ 48 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans.

Subsequent Events Subsequent Ev

Subsequent Events Subsequent Events (Tables)	3 Months Ended
	Mar. 28, 2020
Subsequent Events [Abstract]
Schedule of Subsequent Events [Table Text Block]	Early in the second quarter of 2020, the company issued the following senior notes: (In millions) Principal Value Issued 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) € 600 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) € 600

Allowance For Doubtful Accounts

Allowance For Doubtful Accounts (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable Allowances	$ 101	$ 114		$ 102	$ 117
Provision charged to expense	10	2
Accounts written off	11	$ 5
Acquisitions, currency translation and other	$ (1)
Cumulative Effect, Period of Adoption, Adjustment [Member]
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable Allowances			$ 1

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Current Contract Assets, Net	$ 658	$ 603
Noncurrent Contract Assets, Net	17	17
Current Contract Liabilities	938	916
Noncurrent Contract Liabilities	617	$ 594
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 405

Warranty Obligations (Details)

Warranty Obligations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Warranty Obligations [Roll Forward]
Beginning Balance	$ 93	$ 92
Provision charged to expense	22	27
Usage	(25)	(28)
Adjustments to previously provided warranties, net		(1)
Currency translation	(1)	0
Ending Balance	$ 89	$ 90

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw Materials	$ 1,069	$ 971
Work in Process	503	517
Finished Goods	1,882	1,882
Inventories	$ 3,454	$ 3,370

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	Mar. 28, 2020	Jan. 01, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances	$ 4,508		$ 4,349
Retained earnings	$ 22,791		$ 22,092
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-13 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts Receivable, less Allowances		$ (1)
Retained earnings		$ (1)

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) € / shares in Units, € in Millions, $ in Billions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2021€ / shares	Jun. 30, 2021USD ($)	Mar. 28, 2020EUR (€)
Bridge Loan [Member]
Net Assets Acquired [Abstract]
Maximum Borrowing Capacity | €					€ 9,250
QIAGEN N.V. (Pending Acquisition) [Member]
Net Assets Acquired [Abstract]
Revenue Reported by Acquired Entity		$ 1.5
Forecast [Member] | QIAGEN N.V. (Pending Acquisition) [Member]
Purchase Price
Business Acquisition, Share Price | € / shares			€ 39
Debt to be Assumed				$ 1.4
Estimated Total Purchase Price	$ 11.5

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019
Disaggregation of Revenue [Line Items]
Revenues		$ 6,230	$ 6,125
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	3,287	3,059
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	1,649	1,519
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	1,118	1,363
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	176	184
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,379	3,230
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,251	1,490
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 1,600	$ 1,405
[1]	Revenues are attributed to regions based on customer location.

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Mar. 28, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 8,360
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-28
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	65.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Revenues		$ 6,230	$ 6,125
Cost of revenues charges, net		(2)
Selling, general and administrative charges, net		(6)
Restructuring and other costs, net		(38)	(11)
Amortization of acquisition-related intangible assets		(425)	(422)
Consolidated operating income		906	920
Interest Income		36	67
Interest Expense		(126)	(189)
Other Income, Net		12	19
Income before income taxes		828	817
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(1)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(14)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges, net		(4)
Restructuring and other costs, net		(2)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(2)
Selling, general and administrative charges, net		(2)
Restructuring and other costs, net		(18)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Consolidated operating income	[1]	1,377	1,370
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		1,774	1,607
Consolidated operating income	[1]	675	561
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		1,101	1,322
Consolidated operating income	[1]	171	282
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		958	957
Consolidated operating income	[1]	236	242
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		2,730	2,513
Consolidated operating income	[1]	295	285
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(333)	(274)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(2)	(6)
Selling, general and administrative charges, net		(6)	(11)
Restructuring and other costs, net		(38)	(11)
Amortization of acquisition-related intangible assets		$ (425)	$ (422)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles.

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,230	$ 6,125
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	3,139	2,918
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	464	654
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 2,627	$ 2,553
[1]	Revenues are attributed to countries based on customer location.

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate	21.00%	21.00%
Provision for Income Taxes at Statutory Rate	$ 174	$ 172
Foreign rate differential	(88)	(36)
Foreign exchange loss on inter-company debt refinancing		(62)
Income tax credits	(67)	(72)
Global intangible low-taxed income	61	70
Foreign-derived intangible income	(17)	(12)
Transition tax and other impacts of U.S. tax reform		(20)
Excess tax benefits from stock options and restricted stock units	(28)	(36)
Other, net	5	(2)
Provision for Income Taxes	$ 40	$ 2

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	3 Months Ended
	Mar. 28, 2020USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at Beginning of Year	$ 1,552
Additions for tax positions of current year	2
Settlements	(7)
Balance at End of Period	$ 1,547

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 788	$ 815
Basic Weighted Average Shares	397	400
Effect of Stock Options and Restricted Units	3	3
Diluted Weighted Average Shares	400	403
Basic Earnings Per Share (in dollars per share)	$ 1.99	$ 2.04
Diluted Earnings Per Share (in dollars per share)	$ 1.97	$ 2.02
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	1	2

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 20,151	$ 17,960
Fair Value Hedge Accounting Adjustments	22	(13)
Unamortized Discount, Net	(91)	(94)
Unamortized Debt Issuance Costs	(113)	(101)
Total Borrowings at Carrying Value	19,969	17,752
Less: Short-term Obligations and Current Maturities	738	676
Long-term Obligations	$ 19,231	17,076
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.00%
Total Borrowings at Par Value	$ 66
Total Borrowings at Carrying Value	66
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 19,887	17,736
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated)
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 7, 2020
Effective Interest Rate	0.16%
Total Borrowings at Par Value	$ 668	673
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Effective Interest Rate	2.27%
Total Borrowings at Par Value	$ 557	561
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Effective Interest Rate	2.72%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Effective Interest Rate	4.16%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.94%
Total Borrowings at Par Value	$ 1,114	1,121
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.125%
Debt Instrument, Term	5 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2025
Effective Interest Rate	0.41%
Total Borrowings at Par Value	$ 891	897
Senior Notes [Member] | 4.133% 5-Year Senior Notes, Due 3/25/2025
Debt Instrument [Line Items]
Stated Interest Rate	4.133%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Mar. 25, 2025
Effective Interest Rate	4.28%
Total Borrowings at Par Value	$ 1,100
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total Borrowings at Par Value	$ 713	717
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350	350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 780	785
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200	1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.65%
Total Borrowings at Par Value	$ 557	561
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.50%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2028
Effective Interest Rate	0.77%
Total Borrowings at Par Value	$ 891	897
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 668	673
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 780	785
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Stated Interest Rate	2.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Oct. 1, 2029
Effective Interest Rate	2.74%
Total Borrowings at Par Value	$ 900	900
Senior Notes [Member] | 4.497% 10-Year Senior Notes, Due 3/25/2030
Debt Instrument [Line Items]
Stated Interest Rate	4.497%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 25, 2030
Effective Interest Rate	5.32%
Total Borrowings at Par Value	$ 1,100
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.875%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 1, 2031
Effective Interest Rate	1.13%
Total Borrowings at Par Value	$ 1,003	1,009
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 780	785
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 1, 2039
Effective Interest Rate	1.73%
Total Borrowings at Par Value	$ 1,003	1,009
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400	400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.875%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 1, 2049
Effective Interest Rate	1.98%
Total Borrowings at Par Value	$ 1,114	1,121
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	16	16
Total Borrowings at Carrying Value	$ 16	$ 16

Debt Short-term Financing (Deta

Debt Short-term Financing (Details) - 3 months ended Mar. 28, 2020 € in Millions	USD ($)	EUR (€)	USD ($)
Short-term Financing [Line Items]
Payments of Financing Costs	$ 36,000,000
Expenses Associated with Short-term Financing Commitments	$ 17,000,000
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Maximum Borrowing Capacity			$ 2,500,000,000
Letters of Credit Outstanding, Amount			71,000,000
Line of Credit Facility, Amount Outstanding			$ 0
Bridge Loan [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity | €		€ 9,250
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Debt, Period to Maturity	31 days
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Debt, Interest Rate Swap Arrang

Debt, Interest Rate Swap Arrangements (Details) - USD ($) $ in Millions		Mar. 28, 2020	Dec. 31, 2019
Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Interest Rate Swap, Pay Rate at Period End		2.47%
Cross Currency Interest Rate Contract [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,000
Interest Rate Swap, Pay Rate at Period End		1.17%
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 900	$ 900
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		1.764%
Interest Rate Swap, Pay Rate at Period End	[1]	2.4686%
Interest Rate Swap, Fixed Receive Rate		3.00%
[1]	The payments on $900 million notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of March 28, 2020 from 2.47% to a weighted average of 1.17%.

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 28, 2020USD ($)
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net	$ 70

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 29,675	$ 27,586
Other comprehensive items before reclassifications	(414)
Amounts reclassified from accumulated other comprehensive items	5
Total other comprehensive items	(409)	(11)
Balance	28,559	27,693
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,320)
Other comprehensive items before reclassifications	(357)
Amounts reclassified from accumulated other comprehensive items	0
Total other comprehensive items	(357)
Balance	(2,677)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(71)
Other comprehensive items before reclassifications	(62)
Amounts reclassified from accumulated other comprehensive items	1
Total other comprehensive items	(61)
Balance	(132)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(288)
Other comprehensive items before reclassifications	5
Amounts reclassified from accumulated other comprehensive items	4
Total other comprehensive items	9
Balance	(279)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,679)	(2,498)
Total other comprehensive items	(409)	(11)
Balance	$ (3,088)	$ (2,509)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Assets [Abstract]
Cash equivalents	$ 1,727	$ 1,280
Investments in common stock, mutual funds and other similar instruments	17	19
Warrants	6	6
Insurance contracts	115	131
Derivative contracts	110	37
Total Assets	1,975	1,473
Liabilities [Abstract]
Derivative contracts	32	24
Contingent consideration	54	55
Total Liabilities	86	79
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	1,727	1,280
Investments in common stock, mutual funds and other similar instruments	17	19
Total Assets	1,744	1,299
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	6	6
Insurance contracts	115	131
Derivative contracts	110	37
Total Assets	231	174
Liabilities [Abstract]
Derivative contracts	32	24
Total Liabilities	32	24
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	54	55
Total Liabilities	$ 54	$ 55

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 55	$ 37
Payments	(1)	0
Ending Balance	$ 54	$ 37

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	$ 22	$ (13)
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge	1,016	980
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	22	(13)
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	22
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	20	13
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,000	1,000
Interest Rate Swaps [Member] | Cash Flow Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	750
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,000
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	43	33
Cross Currency Interest Rate Contract [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	10
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	6,109	2,846
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	45	4
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	2	11
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	110	37
Derivative Liabilities	$ 32	$ 24

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized losses on hedging instruments, net of tax	$ (62)	$ 0
Cross Currency Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount Of Derivatives	1,000
Cross Currency Interest Rate Contract [Member] | Other Expense, Net [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(10)
Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount Of Derivatives	6,109		$ 2,846
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	3	2
Currency Exchange Contracts [Member] | Other Expense, Net [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	40	17
Fair Value Hedging [Member] | Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount Of Derivatives	1,000		1,000
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Hedged Debt in Fair Value Hedge	(36)	(28)
Gain (Loss) on Derivative, Net	36	29
Cash Flow Hedging [Member] | Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount Of Derivatives	750
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in OCI on Cash Flow Hedge	(81)	0
Payments for Hedge, Financing Activities	62
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Reclassified from AOCI	(2)	(3)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	83	156
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount Of Derivatives	900		$ 900
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	9	37
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 5	$ 14

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Mar. 28, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ 19,877	$ 18,666
Long-term Debt	19,969	17,752
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	19,795	18,650
Long-term Debt	19,887	17,736
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	66
Long-term Debt	66
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	16	16
Long-term Debt	$ 16	$ 16

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Non-cash Investing and Financing Activities [Abstract]
Declared but unpaid dividends	$ 88	$ 77
Issuance of stock upon vesting of restricted stock units	73	69
Cash and Cash Equivalents	2,981		$ 2,399
Restricted Cash Included in Other Current Assets	27		21
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$ 3,010	$ 1,128	$ 2,422	$ 2,117
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent

Restructuring and Other Costs_3

Restructuring and Other Costs (Income), Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019	May 01, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated less than		0.50%
Cost of Revenues		$ 2
Selling, General and Administrative Expenses		6
Restructuring and other costs, net		38	$ 11
Total Restructuring and Other Costs (Income), Net		46
Restructuring and Related Costs, Cash Costs	[1]	30
Restructuring and Related Costs, Other Costs (Income), Net		9
Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs		23
Abandonment of Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs		4
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	[2]	3
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net		1
Total Restructuring and Other Costs (Income), Net		1
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net		14
Total Restructuring and Other Costs (Income), Net		14
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		4
Restructuring and other costs, net		2
Total Restructuring and Other Costs (Income), Net		6
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		2
Selling, General and Administrative Expenses		2
Restructuring and other costs, net		18
Total Restructuring and Other Costs (Income), Net		22
Impairment of Long-Lived Assets to be Disposed of		8
Laboratory Products and Services [Member] | Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net		10
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net		3
Total Restructuring and Other Costs (Income), Net		$ 3
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs				$ 65
[1]	Excludes $9 million of charges for fixed asset writedowns and costs associated with environmental remediation at an abandoned facility.
[2]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 28, 2020	Mar. 30, 2019
Restructuring Reserve [Roll Forward]
Beginning balance		$ 34
Costs incurred	[1]	30
Reserves reversed	[2]	(1)
Payments		(15)
Ending balance		48
Restructuring and other costs, net		38	$ 11
Restructuring and Related Costs, Other Costs (Income), Net		$ 9
Restructuring Reserve, Expected Final Year of Payments		2020
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		$ 18
Costs incurred		23
Reserves reversed	[2]	(1)
Payments		(10)
Ending balance		30
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		10
Costs incurred		4
Payments		(3)
Ending balance		11
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	[3]	6
Costs incurred	[3]	3
Payments	[3]	(2)
Ending balance	[3]	$ 7
[1]	Excludes $9 million of charges for fixed asset writedowns and costs associated with environmental remediation at an abandoned facility.
[2]	Represents reductions in cost of plans.
[3]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Subsequent Events (Details)

Subsequent Events (Details) € in Millions, $ in Millions	1 Months Ended
	May 01, 2020EUR (€)	Mar. 28, 2020USD ($)	Dec. 31, 2019USD ($)
Subsequent Event [Line Items]
Total Borrowings at Par Value | $		$ 20,151	$ 17,960
Subsequent Event [Member] | Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.75%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2027
Total Borrowings at Par Value	€ 600
Subsequent Event [Member] | Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Apr. 15, 2032
Total Borrowings at Par Value	€ 600